Met inhibitors such as the tyrosine kinase inhibitor cabozantinib are already in clinical trials for advanced prostate cancer [1] and recent trials have shown high MET expression is associated with inferior survival [34]. The gene discussed is MET; the disease is prostate carcinoma.